title: Comparison of drug survival rates for tumor necrosis factor antagonists in rheumatoid arthritis.
abstract: BACKGROUND
  Persistence of anti-tumor necrosis factor (TNF) therapy in rheumatoid arthritis (RA) is an overall marker of treatment success.
  
  
  OBJECTIVE
  To assess the survival of anti-TNF treatment and to define the potential predictors of drug discontinuation in RA, in order to verify the adequacy of current practices.
  
  
  METHODS
  An observational, descriptive, longitudinal, retrospective study.
  
  
  METHODS
  The Hospital Clínico Universitario de Valladolid, Valladolid, Spain.
  
  
  METHODS
  RA patients treated with anti-TNF therapy between January 2011 and January 2012.
  
  
  METHODS
  Demographic information and therapy assessments were gathered from medical and pharmaceutical records. Data is expressed as means (standard deviations) for quantitative variables and frequency distribution for qualitative variables. Kaplan-Meier survival analysis was used to assess persistence, and Cox multivariate regression models were used to assess potential predictors of treatment discontinuation.
  
  
  RESULTS
  In total, 126 treatment series with infliximab (n = 53), etanercept (n = 51) or adalimumab (n = 22) were administered to 91 patients. Infliximab has mostly been used as a first-line treatment, but it was the drug with the shortest time until a change of treatment. Significant predictors of drug survival were: age; the anti-TNF agent; and the previous response to an anti-TNF drug.
  
  
  CONCLUSIONS
  The small sample size.
  
  
  CONCLUSIONS
  The overall efficacy of anti-TNF drugs diminishes with time, with infliximab having the shortest time until a change of treatment. The management of biologic therapy in patients with RA should be reconsidered in order to achieve disease control with a reduction in costs.
authors.affiliation: Pharmacy Department, hospital clínico Universitario de Valladolid, Valladolid, Spain.
authors.forename: Virginia
authors.initials: V
authors.lastname: Martínez-Santana
authors.forename: E
authors.initials: E
authors.lastname: González-Sarmiento
authors.forename: Ma
authors.initials: M
authors.lastname: Calleja-Hernández
authors.forename: T
authors.initials: T
authors.lastname: Sánchez-Sánchez
keywords: biologic agents; drug administration schedule; rheumatoid arthritis; tumor necrosis factor
references.citation: Ann Rheum Dis. 2009 Apr;68(4):552-7
references.pmid: 18467515
references.citation: Arthritis Care Res (Hoboken). 2012 May;64(5):625-39
references.pmid: 22473917
references.citation: Clin Exp Rheumatol. 2012 Jan-Feb;30(1):31-8
references.pmid: 22153557
references.citation: Expert Opin Biol Ther. 2012 Feb;12(2):179-92
references.pmid: 22149260
references.citation: Orv Hetil. 2012 Feb 5;153(5):163-73
references.pmid: 22275731
references.citation: Int J Rheum Dis. 2012 Aug;15(4):e78-9
references.pmid: 22898233
references.citation: Lancet. 2010 Sep 25;376(9746):1094-108
references.pmid: 20870100
references.citation: Arthritis Rheum. 2009 May 15;61(5):560-8
references.pmid: 19405000
references.citation: Rheumatology (Oxford). 2011 Nov;50(11):1999-2004
references.pmid: 21856725
references.citation: Ann N Y Acad Sci. 2009 Sep;1173:837-46
references.pmid: 19758236
references.citation: Br J Dermatol. 2011 May;164(5):1091-6
references.pmid: 21219290
references.citation: Biologics. 2010 Feb 04;4:1-4
references.pmid: 20161980
references.citation: Med Clin (Barc). 2010 May 22;134(15):684-5
references.pmid: 20176386
references.citation: Ann Rheum Dis. 2006 Jun;65(6):746-52
references.pmid: 16339288
references.citation: J Rheumatol. 2011 Jul;38(7):1273-81
references.pmid: 21572150
references.citation: Rheumatology (Oxford). 2008 Apr;47(4):495-9
references.pmid: 18316338
references.citation: Ann Rheum Dis. 2010 May;69(5):817-21
references.pmid: 19581278
references.citation: Clin Ther. 2009 Aug;31(8):1871-80; discussion 1858
references.pmid: 19808146
references.citation: Arthritis Rheum. 2010 Sep;62(9):2569-81
references.pmid: 20872595